Trial Profile
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs CPI-100 (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Coordination Pharmaceuticals
- 19 Jul 2022 Status changed from recruiting to completed.
- 04 Jan 2022 Planned End Date changed from 21 Dec 2021 to 21 Dec 2022.
- 04 Jan 2022 Planned primary completion date changed from 21 Dec 2021 to 21 Jun 2022.